MX369911B - Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia. - Google Patents

Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.

Info

Publication number
MX369911B
MX369911B MX2015012782A MX2015012782A MX369911B MX 369911 B MX369911 B MX 369911B MX 2015012782 A MX2015012782 A MX 2015012782A MX 2015012782 A MX2015012782 A MX 2015012782A MX 369911 B MX369911 B MX 369911B
Authority
MX
Mexico
Prior art keywords
kidney cancer
patient
calculating
gene expression
expression profile
Prior art date
Application number
MX2015012782A
Other languages
English (en)
Other versions
MX2015012782A (es
Inventor
Knezevic Dejan
Shak Steven
Andrew Watson George
R Crager Michael
Maddala Tara
Lopatin Margarita
Goddard Audrey
Svedman Christer
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2015012782A publication Critical patent/MX2015012782A/es
Publication of MX369911B publication Critical patent/MX369911B/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Computing Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método para clasificar un paciente con cáncer de riñón como tendiendo un riesgo superior de recurrencia o un riesgo inferior de recurrencia, caracterizado porque comprende: medir un nivel de transcriptos de ARN de los genes de subconjuntos de genes en una muestra de tumor obtenida del paciente; en donde los subconjuntos de genes son un grupo de gen de normalización vascular, un grupo de respuesta inmunitaria, un grupo de gen de crecimiento / división celular, e IL-6; en donde los genes del grupo de gen de normalización vascular son: APOLD1, EDNRB, NOS3, y PPAP2B, y los genes del grupo de gen de respuesta inmunitaria son: CCL5, CEACAM1, y CX3CL1, y los genes del grupo de gen de crecimiento / división celular son: EIF4EBP1, LMNB1, y TUBB2A; calcular un puntaje de recurrencia al usar el siguiente algoritmo: RS = -0.45 x puntaje del grupo de gen de normalización vascular -0.31 x puntaje del grupo de gen de respuesta inmunitaria + 0.27 x puntaje del grupo de gen de crecimiento/división celular +0.04 x IL5 en donde : puntaje del grupo de gen de normalización vascular =(0.5APOLD1 + 0.5 EDNRB+NOS3 + PPAP2B) /4 puntaje del grupo de gen de crecimiento/división celular = (EIF4EBP1 +1.3LMNB1 + TUBB2A) /3; y puntaje del grupo de gen de respuesta inmunitaria = (0.5CCL5* CEACAM1 + CX3CL1) 3; y clasificar al paciente como riesgo inferior o riesgo superior con base en el puntaje de recurrencia por comparación con riesgo de población promedio para pacientes con cáncer de riñón.
MX2015012782A 2013-05-30 2014-05-29 Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia. MX369911B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829100P 2013-05-30 2013-05-30
PCT/US2014/040003 WO2014194078A1 (en) 2013-05-30 2014-05-29 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Publications (2)

Publication Number Publication Date
MX2015012782A MX2015012782A (es) 2016-02-05
MX369911B true MX369911B (es) 2019-11-26

Family

ID=51989393

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012782A MX369911B (es) 2013-05-30 2014-05-29 Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.
MX2019013953A MX2019013953A (es) 2013-05-30 2015-09-14 Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019013953A MX2019013953A (es) 2013-05-30 2015-09-14 Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.

Country Status (12)

Country Link
US (3) US10181008B2 (es)
EP (2) EP3004392B1 (es)
JP (3) JP2016521979A (es)
AU (2) AU2014274135B2 (es)
CA (2) CA2903878C (es)
DK (1) DK3004392T3 (es)
ES (1) ES2829415T3 (es)
HK (1) HK1223132A1 (es)
IL (2) IL240919B (es)
MX (2) MX369911B (es)
SG (2) SG11201506987VA (es)
WO (1) WO2014194078A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187767A1 (en) * 2017-04-06 2018-10-11 The Regents Of The University Of California Predicting, diagnosing, and treating nausea and vomiting of pregnancy
CN111213209A (zh) * 2017-10-12 2020-05-29 南托米克斯有限责任公司 根据生物体液的评估用癌症评分和反应预测
KR102280204B1 (ko) * 2018-12-13 2021-07-21 연세대학교 산학협력단 신장 세포 암의 종양의 병리학적 등급에 대한 정보를 제공하기 위한 방법 및 장치
CA3126455A1 (en) * 2019-01-11 2020-07-16 Quadrus Medical Technologies, Inc. Systems and methods for assessing and evaluating renal health diagnosis, staging, and therapy recommendation
EP3978629A1 (en) * 2020-10-01 2022-04-06 Koninklijke Philips N.V. Prediction of an outcome of a bladder or kidney cancer subject
CN113593640B (zh) * 2021-08-03 2023-07-28 哈尔滨市米杰生物科技有限公司 一种鳞癌组织功能状态与细胞组分评估方法及系统

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135314B1 (en) 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
CA2397207C (en) 2000-01-13 2013-12-03 Genentech, Inc. Novel stra6 polypeptides
US6475855B1 (en) 2000-03-01 2002-11-05 Micron Technology, Inc. Method of forming integrated circuitry, method of forming a capacitor and method of forming DRAM integrated circuitry
DE10126344A1 (de) 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
WO2002027028A1 (en) 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
WO2002074237A2 (en) 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
EP1410011B1 (en) 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
US7470509B2 (en) 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
JP2005519624A (ja) 2002-03-13 2005-07-07 ジェノミック ヘルス， インコーポレイテッド 生検腫瘍組織での遺伝子発現プロファイリング
CA2501131A1 (en) 2002-10-04 2004-04-22 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
US7611839B2 (en) 2002-11-21 2009-11-03 Wyeth Methods for diagnosing RCC and other solid tumors
CA2523798A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
PL3470535T3 (pl) 2003-06-24 2020-08-24 Genomic Health, Inc. Prognozowanie prawdopodobieństwa ponownego wystąpienia raka
CN1845999A (zh) 2003-07-02 2006-10-11 诺瓦提斯公司 在卵巢癌中作为预后和治疗靶标而被调控的基因
US20050002904A1 (en) 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US7871769B2 (en) * 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
US7482129B2 (en) * 2004-05-04 2009-01-27 Institute Of Virology, Slovak Academy Of Sciences MN/CA IX/CA9 and Renal Cancer Prognosis
AU2005249446A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of IMPDH pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080119367A1 (en) 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
MX2007010001A (es) 2005-02-18 2007-09-27 Wyeth Corp Marcadores farmacogenomicos para el pronostico de tumores solidos.
WO2006124022A1 (en) 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
JP5904569B2 (ja) 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006134468A1 (en) 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles for use against parasitites
EP2154245B1 (en) 2005-09-02 2015-11-11 Toray Industries, Inc. Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
CN101292046B (zh) 2005-09-14 2013-03-13 人类遗传标记控股有限公司 健康状态的测定法
EP2332984A3 (en) 2005-09-30 2011-10-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
JP2009523709A (ja) 2005-12-16 2009-06-25 ジェネンテック・インコーポレーテッド 神経膠腫の診断、予後の予測及び治療の方法
US20080242606A1 (en) 2006-06-06 2008-10-02 Zhong Jiang Use of IMP3 as a Prognostic Marker for Cancer
EP2046973A4 (en) 2006-08-10 2010-04-07 Millennium Pharm Inc METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
WO2008083098A1 (en) * 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
GB2477705B (en) 2008-11-17 2014-04-23 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
CA2766703A1 (en) 2009-06-26 2010-12-29 Noviogendix Research B.V. Molecular markers in kidney cancer
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
ES2735993T3 (es) * 2009-11-23 2019-12-23 Genomic Health Inc Métodos para predecir el resultado clínico del cáncer
WO2011085263A2 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA2839530A1 (en) * 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
WO2013028807A2 (en) * 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
US11551782B2 (en) 2023-01-10
US10181008B2 (en) 2019-01-15
CA3093128A1 (en) 2014-12-04
CA3093128C (en) 2023-01-03
IL240919A0 (en) 2015-10-29
US20160048632A1 (en) 2016-02-18
DK3004392T3 (da) 2020-10-26
AU2014274135B2 (en) 2020-04-09
IL240919B (en) 2021-06-30
CA2903878C (en) 2020-10-27
MX2019013953A (es) 2020-01-30
AU2020204502B2 (en) 2022-02-17
EP3004392A4 (en) 2017-01-25
NZ752676A (en) 2021-05-28
SG11201506987VA (en) 2015-10-29
EP3825420A1 (en) 2021-05-26
US20220044760A9 (en) 2022-02-10
AU2020204502A1 (en) 2020-07-23
JP7301798B2 (ja) 2023-07-03
SG10201709537PA (en) 2017-12-28
AU2014274135A1 (en) 2015-09-24
HK1223132A1 (zh) 2017-07-21
IL283548A (en) 2021-07-29
JP2018161151A (ja) 2018-10-18
US20190095575A1 (en) 2019-03-28
EP3004392A1 (en) 2016-04-13
MX2015012782A (es) 2016-02-05
ES2829415T3 (es) 2021-05-31
US20210151122A1 (en) 2021-05-20
JP2020191896A (ja) 2020-12-03
JP2016521979A (ja) 2016-07-28
NZ711680A (en) 2021-05-28
EP3004392B1 (en) 2020-09-30
WO2014194078A1 (en) 2014-12-04
CA2903878A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
WO2014144121A3 (en) Classification and actionability indices for lung cancer
DK3080585T3 (da) Biosensorer til biologisk eller kemisk analyse og fremgangsmåder til fremstilling heraf
EP3971299A3 (en) Colorectal cancer detection kit or device, and detection method
EP3744859A3 (en) Microrna biomarker for the diagnosis of gastric cancer
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
BR112016029583A2 (pt) ?kit ou dispositivo para a detecção de câncer esofágico e método de detecção?
IN2014DN08831A (es)
EP3800253A3 (en) Prostate cancer detection kit or device, and detection method
EP2576837A4 (en) CIRCULATING NUCLEIC ACID BIOMARKERS ASSOCIATED WITH PROSTATE CANCER
BR112016027222A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
EP2619587A4 (en) BIOMARKERS FOR RECURRENCE PREDICTION OF COLORECTAL CANCER
UA115321C2 (uk) Спосіб та комплект для аналізу ahasl генів у рослин
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
EA201501137A1 (ru) Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac
WO2015148645A3 (en) Methods and kits for the prognosis and treatment of prostate cancer
WO2013190468A3 (en) Computer-based predictor for prostate cancer
WO2017007739A3 (en) Nucleic acid probes
GB201210864D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration